Connor Webb: IL-6 as a Primer of Platelet Hyperresponsiveness
Connor Webb, PHD Student at The University of Bristol, shared on LinkedIn about a recent article he and his colleagues co-authored, published in Cells MDPI, adding:
”One year ago, Jordan Vautrinot, Ingeborg Hers and I published our review proposing IL-6 as a primer of platelet hyperresponsiveness involved in cardiovascular and inflammatory diseases.
We argued that IL-6 trans-signalling via gp130, with selective crosstalk into the GPVI/collagen pathway, offered a mechanistically plausible explanation for why IL-6 is repeatedly invoked as a potential thrombo-inflammatory factor across a range of inflammatory conditions and complications (from COVID-19 to stent thrombosis).
Since then, there has been some great experimental work that directly evaluated several of the mechanisms we proposed.
Ministrini and colleagues (2025; ATVB; 45:1432) showed in mice that an IL-6 antibody selectively blunted platelet reactivity to GPVI/collagen stimulation but not to PAR-1 or P2Y12, and replicated the finding ex vivo in platelets from patients at high cardiovascular risk.
New IL-6-targeted modalities continue to emerge, and in September 2025, Novartis acquired Tourmaline Bio for approximately £1B to advance the drug pacibekitug, a long-acting IL-6 antibody, for ASCVD.
Two large cardiovascular trials involving IL-6 therapy are also rapidly approaching completion.
The ZEUS trial (estimated June 2026) is evaluating ziltivekimab in patients with established ASCVD, chronic kidney disease and systemic inflammation.
ARTEMIS is a phase 3 study of ziltivekimab as an acute therapy in patients hospitalised with acute myocardial infarction.
It was satisfying seeing some of our theories confirmed, but equally, many new questions arise about the safety, selectivity, and appropriateness of IL-6 blockade alongside existing antithrombotic strategies… in such a rapidly evolving field, nothing is for certain.
If you missed our review, please have a read.”
Title: IL-6 as a Mediator of Platelet Hyper-Responsiveness
Authors: Connor Webb, Jordan Vautrinot, Ingeborg Hers
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 28, 2026, 19:01Aseemita Debata: First Trimester – Common Problems and Possible Complications
-
Aug 28, 2026, 18:58Jason Carney: Challenging Long-Standing Assumptions About Women and Anemia
-
Aug 28, 2026, 17:16ASH 2026 Guideline on ITP: Evolving Treatment Strategies
-
Aug 28, 2026, 16:44HEMGENIX Supply Update for the Hemophilia B Community – National Bleeding Disorders Foundation
-
Aug 28, 2026, 16:39Maria Elisa Mancuso: Attending EHC 2026 Annual Conference in Istanbul
-
Aug 28, 2026, 16:25Manali Kakadia: Evaluation and Management of Recurrent Epistaxis
-
Aug 28, 2026, 16:18Navigating Higher Education with a Bleeding Disorder – Bleeding Disorders Council of California
-
Aug 28, 2026, 16:11Maia Meier: Reaching New Heights for Women With Inherited Bleeding Disorders
-
Aug 28, 2026, 15:10Ify Osunkwo: Strengthening Sickle Cell Care Systems at Global Conference in Nairobi